Myriad Genetics (MYGN) said Wednesday the US Patent and Trademark Office issued two new patents to the company, further advancing the process of its molecular residual disease assay.
US patent No. 12,215,391 relates to proprietary automated methods to carry out molecular residual disease analysis, the company said late Wednesday. Patent No. 12,215,392 relates to the "patient journey" aspects of the disease.
The assay will be able to tell clinicians and patients if the treatment is and if the cancer has recurred, Myriad Chief Executive Paul Diaz said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。